ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO0664

SIRT3 Suppresses Cyst Growth via Enhancing Mitochondrial Function in ADPKD

Session Information

Category: Genetic Diseases of the Kidneys

  • 1201 Genetic Diseases of the Kidneys: Monogenic Kidney Diseases

Authors

  • Liu, Chang, Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Zhang, Yueyue, Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Cheng, Shasha, Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Harris, Peter C., Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Li, Xiaogang, Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Zhou, Xia, Mayo Clinic Minnesota, Rochester, Minnesota, United States
Background

ADPKD is characterized by progressive cyst formation leading to kidney failure. Mitochondrial dysfunction has been recognized as a pathogenetic factor of ADPKD. Polycystin 1 (PC1) undergoes a cleavage to form a C-terminal tail fragment (PC1-CTT) that translocates to nuclei and mitochondria to regulate signaling pathways. SIRT3, the primary mitochondrial NAD+-dependent deacetylase, enhances the functions of mitochondrial proteins, mitochondrial biogenesis and dynamics, and metabolic stability. However, the role of SIRT3 in regulating mitochondrial dysfunction in ADPKD and the interplay of SIRT3 and PC1-CTT remain unknown.

Methods

To understand the role of SIRT3 in vivo, Pkd1RC/RC and Pkd1fl/fl;Pkhd1-Cre mice were treated with SIRT3 activator honokiol. To explore the mechanisms mediated by SIRT3 in regulating cyst growth, Pkd1 mutant cells were overexpressed with SIRT3 and treated with honokiol. To determine the interplay of SIRT3 and PC1-CTT, immunoprecipitation was performed.

Results

The expression of SIRT3 mRNA and protein were downregulated in Pkd1 mutant renal epithelial cells and kidney tissues. Treatment with honokiol attenuated cyst progression in the kidneys of Pkd1RC/RC and Pkd1fl/fl;Pkhd1-Cre mice as seen by a decrease in cystic index, kidney weight/body weight ratios, blood urea nitrogen levels, and cystic lining epithelial cell proliferation. We found that SIRT3 protected renal epithelial cells from oxidative stress by deacetylating SOD2, thereby inhibiting the activation of Akt-mTOR pathway. Treatment with honokiol also led to a decrease of fragmentation and an improvement of elongation and interconnection of mitochondria. SIRT3 regulated the balance of fission and fusion through deacetylating its novel substrate, mitochondrial fission factor (MFF). SIRT3 colocalized and interacted with PC1-CTT in mitochondria, and deacetylated PC1-CTT. In addition, nuclear PC1-CTT promotes the transcription of SIRT3 through its interaction with PGC1α.

Conclusion

The downregulation of SIRT3 promotes mitochondrial dysfunction and cyst growth in ADPKD by hyperacetylation of mitochondrial enzymes and PC1-CTT, which is transcriptionally regulated by nuclear PC1-CTT, forming a nuclear-mitochondrial regulatory axis of SIRT3-PC1-CTT. This study suggests that the activation of SIRT3 with activators, such as honokiol, may be a promising therapeutic strategy for ADPKD.

Funding

  • Private Foundation Support

Digital Object Identifier (DOI)